Results 31 to 40 of about 3,307,905 (304)
Epitope-based vaccines for cancer
, 2011 INTRODUCTION Epitope-based cancer vaccination, comprised of minimal immunogenic portions of a cancer antigen, represents an immunotherapy that combines target specifi city with long-lasting immunity. Advances in epitope identifi cation and immunogenicity
core +1 more source
Human Papillomavirus Vaccines: An Updated Review
, 2020 Human papillomavirus (HPV) vaccines, which were introduced in many countries in the past decade, have shown promising results in decreasing HPV infection and related diseases, such as warts and precancerous lesions. In this review, we present the updated
Cheng, L, +5 more
core +1 more source
Scientific Reports, 2018 The human T-cell leukemia virus type 1 (HTLV-1) is highly dependent on cell-to-cell interaction for transmission and productive infection. Cell-to-cell interactions through the virological synapse, biofilm-like structures and cellular conduits have been ...
Maria Omsland +8 more
doaj +1 more source
Improving cellular cancer vaccines [PDF]
, 2010 Immunization with cancer cells is of great demand in anti-cancer therapy. However, current cellular vaccines are inefficient and there are questions regarding their overall safety. We report a simple and straightforward approach for improving of cellular
Petr Lokhov
core
Engineering New Approaches to Cancer Vaccines [PDF]
, 2015 available in PMC 2016 August 01Recently, a number of promising approaches have been developed using synthetic chemistry, materials science, and bioengineering-based strategies to address challenges in the design of more effective cancer vaccines.
Irvine, D. J. +2 more
core +1 more source
Engineering peptides into antibodies—opportunities and strategies for therapeutic innovation
FEBS Letters, EarlyView.Peptides and antibodies occupy complementary therapeutic niches. Peptides recognize difficult targets in a compact format, while antibodies add specificity, long half‐life, and effector functions. This review examines strategies that merge both modalities—peptide grafting into loops, terminal and Fc fusions, and bioconjugation—highlighting how ...
Jinling Wang +2 more
wiley +1 more source
Vaccines Against Non-Infectious, Non-Cancer Novel Targets
, 2015 This chapter discusses vaccines against non-infectious, non-cancer novel targets. It is part of a collection which takes a look at the current strategies, successes and challenges involved with the development of novel formulations of biologics, vaccines
Nimmo, Natalie +7 more
core +4 more sources
p30 protein: a critical regulator of HTLV-1 viral latency and host immunity
Retrovirology, 2019 The extraordinarily high prevalence of HTLV-1 subtype C (HTLV-1C) in some isolated indigenous communities in Oceania and the severity of the health conditions associated with the virus impress the great need for basic and translational research to ...
Ramona Moles +8 more
doaj +1 more source
Targeting purinergic pathway to enhance radiotherapy-induced immunogenic cancer cell death
Journal of Experimental & Clinical Cancer Research, 2022 Emerging evidence has demonstrated that radiotherapy (RT) can not only cause direct damage to cancer cells but also lead to immunogenic cell death (ICD), which involves the activation of host antitumor immune response in tumor immune microenvironment ...
Xuhui Bao, Liyi Xie
doaj +1 more source
BMJ, 2015 Cancer vaccines are designed to promote tumor specific immune responses, particularly cytotoxic CD8 positive T cells that are specific to tumor antigens. The earliest vaccines, which were developed in 1994-95, tested non-mutated, shared tumor associated antigens that had been shown to be immunogenic and capable of inducing clinical responses in a ...
openaire +3 more sources